PET在弥漫性肺疾病功能成像中的应用综述
本文综述了PET作为一种定量分子影像技术在弥漫性肺疾病(DLD)研究中的应用,强调其可对分子靶向过程进行无创分子表型分析。目前PET监测DLD疾病进展和治疗反应主要限于临床试验研究,临床应用有限。文章重点介绍了处于临床开发阶段的新型示踪剂用于DLD分子表型分析,并简要讨论了准确量化肺PET信号的考虑因素。
要点
- PET可提供CT解剖分类之外的分子表型信息,有助于DLD的临床表征。
- 目前PET监测DLD疾病进展和治疗反应多限于研究性临床试验。
- 新型示踪剂正处于临床开发阶段,用于DLD分子表型分析。
局限性
- PET在DLD中监测疾病进展和治疗反应的应用多限于研究性临床试验,临床实践有限。
- 肺PET信号定量存在考虑因素,可能影响准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Positron emission tomography (PET) is a quantitative molecular imaging modality increasingly used to study pulmonary disease processes and drug effects on those processes. The wide range of drugs and other entities that can be radiolabeled to study molecularly targeted processes is a major strength of PET, thus providing a noninvasive approach for obtaining molecular phenotyping information. The use of PET to monitor disease progression and treatment outcomes in DLD has been limited in clinical practice, with most of such applications occurring in the context of research investigations under clinical trials. Given the high costs and failure rates for lung drug development efforts, molecular imaging lung biomarkers are needed not only to aid these efforts but also to improve clinical characterization of these diseases beyond canonical anatomic classifications based on computed tomography. The purpose of this review article is to provide an overview of PET applications in characterizing lung disease, focusing on novel tracers that are in clinical development for DLD molecular phenotyping, and briefly address considerations for accurately quantifying lung PET signals.
引用
- Gulhane, Chen. Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases. Br J Radiol. 2021. PMID: 34752146. doi:10.1259/bjr.20210824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。